The Assessment of Patient-Reported Outcomes in the Medical Management of Patients With Benign Prostatic Hyperplasia

Malik Adil Mehmood; Shah Jehan; Issa Khan; Muhammad Ilyas; Usama Khan; Wajid Ali

doi:10.7759/cureus.67027

The Assessment of Patient-Reported Outcomes in the Medical Management of Patients With Benign Prostatic Hyperplasia

Cureus. 2024 Aug 16;16(8):e67027. doi: 10.7759/cureus.67027. eCollection 2024 Aug.

Authors

Malik Adil Mehmood¹, Shah Jehan², Issa Khan¹, Muhammad Ilyas³, Usama Khan⁴, Wajid Ali⁵

Affiliations

¹ Urology, Institute of Kidney Diseases, Peshawar, PAK.
² Urology, Maqsood Medical Complex (MMC) General Hospital, Peshawar, PAK.
³ Urology, Nizwa hospital, Nizwa, OMN.
⁴ General Practice, Category D Hospital, Razmak, PAK.
⁵ Surgery, Hayatabad Medical Complex, Peshawar, PAK.

Abstract

Background Benign prostatic hyperplasia (BPH) is a prevalent condition that a large portion of the male population develops with aging, in which the prostate gland enlarges and results in urinary symptoms. Objective The objective of this article is to assess patient-reported outcomes (PRO) of medical management of benign prostate hyperplasia in terms of international prostate symptoms score (IPSS), BPH impact index (BPHII), and treatment satisfaction score (TSS). Methods This descriptive study included 114 patients who received medical management for BPH during the period 5^th May 2021 till 30^th December 2023, at the Department of Urology, Institute of Kidney Disease Peshawar. Patient-reported outcomes were measured in terms of IPSS, BPHII, and TSS. Readings were recorded at the start of treatment and at three months of treatment and then compared. Data was analyzed using SPSS v.25 (IBM Inc., Armonk, New York). Results The mean age of the patients was 64.33 ± 6.12 years. The mean prostate size was 77.35 ± 12.83 ml. Overall mean pre-treatment and post-treatment IPSS was 24.82 ± 4.90 versus 15.57 ± 5.15, respectively (p-value 0.00). Mean pre-treatment and post-treatment BPHII were 11.98 ± 1.02 and 7.12 ± 2.46, respectively (p-value 0.000). The overall mean treatment satisfaction score was 6.89 ± 1.44. Conclusion Medical management improved symptomatology in BPH patients. This study is a step in the direction of the development of larger and longer-term PRO studies in BPH management.

Keywords: benign prostate enlargement; benign prostate hyperplasia impact index; conservative medical management; international prostate symptom score; patient-reported outcome.